Scopus BioPharma’s Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society

NEXT STORY
AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19
PREV STORY
Neovasc REDUCER-I Study Published in EuroIntervention Journal
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Adaptimmune Announces New Vice President of Business Development, Wenyong Wang

PHILADELPHIA and OXFORD, United Kingdom, April 18, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ...

author_avatar
NASDAQ Market News

Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections

PDUFA action date set for February 13, 2019NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) ...

author_avatar
NASDAQ Market News

Amarin Announces First Middle East Approval for Vascepa®

BEDMINSTER, N.J. and DUBLIN, Ireland, March 21, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), ...

author_avatar
NASDAQ Market News